Advanced searches left 3/3

Metastatic Breast Cancer - Springer Nature

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer

Background: Metastatic breast cancer and the circulating tumor cells contributing to macrometastases are inherently different from primary breast cancer. Methods We performed RNA-Seq on fresh metastatic tumor biopsies, CTCs, and peripheral blood from 19 newly diagnosed MBC patients. Compared to similar metastases and PB, CTCs had higher levels of immune oncology targets. Conclusion We find that RNA-Seq of CTCs can act as a survivor of breast cancer macrometastasis and provide clinically relevant information about disease biology and clinically actionable goals.

Source link: https://doi.org/10.1245/s10434-021-11135-2


Unmet needs and problems related to employment and working as reported by survivors with metastatic breast cancer

Purpose: The U. S. population living with metastatic breast cancer has surpassed 165,000 by 2020, according to Purpose. We attempted to identify the work status, importance of work, and work-related information for women living with MBC. Methods We carried out an online survey in 2014–2015 using an MBC listserv and clinic flyers. Respondents working at MBC diagnosis were divided into "stably-working" and "no-longer-working" according to the survey's status at the time of the examination. When compared to no-working, the stably-working respondents received more detailed advice on how to communicate with employers or coworkers about diagnosis, human rights in employment, when to consider layoffs, and applying for disability. Conclusion The decision to stop working could have triggered a subsequent event triggered by cancer progression. This report shows that there is an increasing shortage of data targeting MBC to support job and financial issues early in the MBC cycle, according to this report.

Source link: https://doi.org/10.1007/s00520-021-06755-z


Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study

According to BRCA and hormone receptor status, the aim of this study was to investigate real-world clinical outcomes in patients with BRCA-mutated HER2-negative metastatic breast cancer patients with BRCA-mutated, HER2-negative metastatic breast cancer. According to BRCA status and HR status, Time to first subsequent therapy or death from the date of mBC diagnosis and the start of first-line treatment for mBC and general health from the date of mBC diagnosis and overall survival from the date of mBC diagnosis and overall survival from the date of mBC diagnosis were investigated. Results 3744 patients with HER2-negative mBC were identified among 3744 patients. Regardless of BRCA status, patients with HER2-negative mBC were broadly similar, including TA and OS.

Source link: https://doi.org/10.1007/s10549-022-06541-3


A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer

This descriptive systematic review examined the connection between personality and QoL in women with non-metastatic breast cancer. There was a slight to moderate influence of personality on QoL, from 0. 10 to 0. 77 percent, and the explained variance ranged from 4 to 43 percent. On psychosocial QoL domains, the relationship was based on the individual trait and QoL domain that was assessed, and was most apparent for the personality traits of "optimism" and "trait anxiety" on psychosocial QoL domains. Conclusions The results confirm that personality plays a role in QoL in women with non-metastatic breast cancer, providing evidence that personality traits are indeed significant predictors of QoL. Psycho-oncological support or therapy can help physicians and patients determine whether or deterioration of QoL has provided physicians and patients with an interpretation of low or deterioration of QoL, which may lead to physicians' and patients' health problems, as well as QoL's deterioration, which may cause physicians to monitor their patients' health and ultimately QoL.

Source link: https://doi.org/10.1186/s12885-022-09408-4


Transcription factor Runx2 changes the expression of some matricellular proteins in metastatic breast cancer cells

Background Runx2 is one of the runt-related genes that are overexpressed in human cancers and contribute to metastasis. Modifications of the extracellular matrix and decrease in cell-cell contact are required to cure cancer cell metastasis. This research was designed to investigate the effect of the Runx2 transcription factor on the expression of matricellular proteins like HPA1, LOX, SPARC, and OPN, which are all important in ECM reconstruction and ECM-cell interactions in human breast cancer. MDA-MB-231 human metastatic breast cancer cells were diagnosed with runx2 siRNA, according to the method and results. The qPCR and Western blotting experiments showed that ECM proteins' changes in the mRNA and protein expressions were shown by the changes in the mRNA and protein expressions, respectively. Thus, we have found that runx2 appears to be able to control breast cancer metastasis through an expression of matricellular proteins.

Source link: https://doi.org/10.1007/s11033-022-07457-3


Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Methods - 170 kinase inhibitors were added to MCF-7 cells either with adaptative or genetic resistance to ET drugs, but both ER levels and cell proliferation were measured. The resulting ER-positive BCs have a longer RFS in women with a longer RFS. When speaking low CHK1 levels, women wearing luminal A BC have an extended RFS. According to ER-positive BC cell lines, CHK1 and ER activation are linked, while the ATR:CHK1 pathway regulates ER stability and cell proliferation in luminal A BC cells. CHK1 inhibitors, which E2:ER signaling to cell proliferation, has been impeded by CHK1 inhibition in primary and MBC clinical trials for the treatment of solid tumors in preventing cell proliferation.

Source link: https://doi.org/10.1186/s13046-022-02360-y


Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China

Here, we analyzed the relationship between age at first diagnosis and rMBC mortality in China. Methods included in this study were a total of 1636 women diagnosed with rMBC between 1989 and 2020 at West China Hospital, Sichuan University. After accounting for demographics, tumor characteristics, and treatment methods, elderly patients had a 70% greater risk of post-metastasis death in comparison to middle-aged patients. In the same manner, elderly patients were found with a 75% higher risk of post-metastasis mortality relative to younger patients. Conclusions Our results indicate that in breast cancer, elderly patients with initial diagnosis are at a higher risk of post-metastasis mortality.

Source link: https://doi.org/10.1186/s12885-022-09454-y


Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

In a paired analysis using these two methods, a prospective review compares CTC enumeration in patients with breast cancer. Enumeration was carried out on 100 samples obtained from 86 patients with progressive metastatic breast cancer in two separate laboratories, each blinded to the clinical results and the others from the other platform. With a median of 3 CTCs ranging from 0 to 2289, the RareCyte CTC numbers ranged from 0 to 2289, with a median of 3 CTCs. The number of samples containing 5 or more CTCs in 7. 5 mL of blood was 45% with the CellSearch test and 48% with the RareCyte technique. Conclusion Our results reveal the comprehensive and prognostic equivalence of CellSearch and RareCyte CTC enumeration schemes in patients with MBC using the CellSearch cut-off.

Source link: https://doi.org/10.1007/s10549-022-06585-5


FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study

Objectives: To determine if radiometrics with machine learning can distinguish between F-18-fluorodeoxyglucose -ample breast cancer metastatic lymphadenopathy and FDG-avid COVID-19 mRNA vaccine–related axillary lymphadenopathy, see Table 1. FDG-positive, pathology-proven, metastatic axillary lymph nodes in 53 breast cancer patients who underwent PET/CT for follow-up or staging, and FDG-positive axillary lymph nodes in 46 patients who were vaccinated with the COVID-19 mRNA vaccine in 46 patients were retrospectively evaluated. Patients who were vaccinated with the COVID-19 mRNA vaccine had FDG-avid reactive axillary lymph nodes in PET scans, according to FDG-avid reactive axillary lymph nodes. • We investigated whether radiomics and machine learning could distinguish between FDG-avid metastatic lymphadenopathy in breast cancer patients and FDG-responsive axillary lymph nodes. • Combined PET and CT radiomics results established a good test AUC for distinguishing between metastatic axillary lymphadenopathy and post-COVID-19 vaccine-associated axillary lymphadenopathy in axillary lymphadenopathy.

Source link: https://doi.org/10.1007/s00330-022-08725-3


Locoregional tumor burden and risk of mortality in metastatic breast cancer

The role of lymph node involvement and tumor size in metastatic disease, particularly breast cancer, is unclear. In the Surveillance, Epidemiology, and End Results Program database in the United States, nodal metastasis and T stage on mortality were investigated in a de novo metastatic breast cancer population. Nodal involvement and T stage, therefore, are independent risk factors for mortality in the population of de novo metastatic breast cancer.

Source link: https://doi.org/10.1038/s41698-022-00265-9

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions